XCX Stock Overview
Greenrise Global Brands Inc. does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Greenrise Global Brands Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.005 |
| 52 Week High | CA$0.085 |
| 52 Week Low | CA$0.005 |
| Beta | -0.055 |
| 1 Month Change | -66.67% |
| 3 Month Change | n/a |
| 1 Year Change | -83.33% |
| 3 Year Change | -98.75% |
| 5 Year Change | -96.43% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| XCX | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -0.6% |
| 1Y | -83.3% | -1.1% | 3.9% |
Return vs Industry: XCX underperformed the Canadian Healthcare industry which returned -1.1% over the past year.
Return vs Market: XCX underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| XCX volatility | |
|---|---|
| XCX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: XCX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine XCX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Stefan Feuerstein | greenriseglobal.com |
Greenrise Global Brands Inc. does not have significant operations. It was previously engaged in the supply of medical cannabis products. The company was formerly known as AMP Alternative Medical Products Inc. and changed its name to Greenrise Global Brands Inc. in November 2021.
Greenrise Global Brands Inc. Fundamentals Summary
| XCX fundamental statistics | |
|---|---|
| Market cap | CA$236.18k |
| Earnings (TTM) | -CA$694.38k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs XCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XCX income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €474.05k |
| Earnings | -€474.05k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -106.0% |
How did XCX perform over the long term?
See historical performance and comparison